Micafungin Accord

Micafungin, the active ingredient in Micafungin Accord, is an echinocandin antifungal presented as an intravenous injection solution for intravenous use. It treats invasive Candida infections and is used for prophylaxis in patients undergoing hematopoietic stem cell transplantation. GNH USA supplies Micafungin Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Micafungin Accord is an echinocandin antifungal indicated for several serious Candida infections. - Invasive candidiasis: eradicates bloodstream and deep‑tissue Candida infections. - Esophageal candidiasis: clears fungal lesions in the esophagus. - Candidemia: eliminates Candida organisms from the blood. - Prophylaxis in hematopoietic stem cell transplantation: prevents Candida infection during immune suppression.

Micafungin Accord may cause adverse reactions that vary in frequency and severity.

Common Side Effects: - Elevated liver enzymes: transient increase in ALT or AST. - Fever: mild to moderate temperature rise. - Nausea: occasional gastrointestinal discomfort. - Headache: mild, self‑limiting.

Serious or Rare Side Effects: - Hepatotoxicity: significant liver injury requiring monitoring. - Severe hypersensitivity: rash, angioedema, or anaphylaxis. - Infusion-related reactions: hypotension, dyspnea, or chest discomfort.

Before initiating therapy, consider the following safety measures. - Liver function monitoring: assess baseline enzymes and repeat during treatment. - Renal function assessment: adjust use in severe renal impairment if needed. - Concomitant antifungal therapy: avoid overlapping agents with similar mechanisms. - Pregnancy and lactation: use only if benefits outweigh potential risks. - Storage: Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin may interact with other medicines; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid): - Cyclosporine: increased cyclosporine exposure may raise toxicity risk. - Rifampin: may reduce micafungin plasma concentrations, compromising efficacy.

Moderate Interactions (Monitor Closely): - Azole antifungals (e.g., fluconazole): potential additive hepatotoxicity. - Immunosuppressants (e.g., tacrolimus): monitor drug levels for possible changes. - Warfarin: observe INR for any alteration in anticoagulant effect.